GLP-1

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy…

Novo Nordisk is running an exhibition in central London designed to start a dialogue on obesity and help…

Novo Nordisk (NVO) CEO Mike Doustdar pushed back Wednesday against the prevailing investor narrative that the booming obesity…

After kickstarting the GLP-1 wave that transformed the pharma landscape and briefly sending its market value above Denmark’s…

Two of the world’s largest pharmaceutical companies are riding the wave of popularity of GLP-1 drugs, which have led…

Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with…

Q: What is Novo Nordisk’s current positioning in the Mexican market, and what are the primary factors driving…

Novo Nordisk has escalated its legal confrontation with Eli Lilly, filing for a preliminary injunction in a New…

A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by…

Novo Nordisk filed a lawsuit against rival Eli Lilly, accusing the latter of false advertising regarding weight-loss medications.…

GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a…

Topline Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company…

Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill